Science journalism · Not medical advice Regulatory window · PCAC review concluded

Peptide reference

AOD-9604

AOD-9604

Animal data

A fragment of the C-terminal region of human growth hormone, designed to replicate the fat-metabolising activity of hGH without the growth-promoting or insulin-sensitising effects. Phase II/III trials for obesity ran in the early 2000s; primary efficacy endpoints weren't met at meaningful effect sizes. It received Generally Recognized as Safe (GRAS) status from the FDA for food use in 2014 — a distinct regulatory track from drug approval. On the PCAC July 2026 docket.

FDA status
No FDA drug approval. FDA GRAS status for food use (2014). Under PCAC July 23–24 2026 review for potential 503A bulk substance listing.
WADA status
Not applicable
Route
subcutaneous injection; oral (trials)

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on AOD-9604

AOD-9604: The Growth Hormone Fragment That Failed Its Own Trial

WADA

AOD-9604 isolates the fat-burning piece of growth hormone from the piece that makes you grow. Whether that clean design actually worked in a human body, and what regulators decided about it, is the open question here.

aod-9604

503B outsourcing pharmacies and compounded peptides: the regulatory gap that still matters

Section 503B outsourcing facilities are the higher-volume, FDA-inspected cousin of the corner compounding pharmacy. The 503B Bulks List is its own regulatory pipeline — and it changes what an actual peptide supply chain looks like when one opens.

bpc-157
tb-500
kpv
mots-c
aod-9604

AOD-9604 and adiponectin: the fat-loss signal that skips growth hormone

WADA

Most fat-loss peptides work by turning up your whole growth-hormone system and hoping the fat follows. AOD-9604 skips that and talks to the fat cell directly — a cleaner idea. Here is how the mechanism works, why your fat is a hormone-producing organ, and how far the human proof actually goes.